Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations: results from the Phase II BEAVER trial

Abstract Class 2 and 3 non-V600E BRAF mutations are oncogenic drivers in many cancer types. Currently, there are no established targeted therapies with proven efficacy for cancers with non-V600E BRAF mutations. We developed the investigator-initiated, Phase II BEAVER clinical trial (NCT03839342) to...

Descrizione completa

Dettagli Bibliografici

Autori principali:	April A. N. Rose, Jennifer Maxwell, Emmanuelle Rousselle, Chantel L. Mukonoweshuro, Islam E. Elkholi, Melody Riaud, Marco Biondini, Erica Cianfarano, Isabel Soria-Bretones, Chantal Tobin, Meghan McGuire, Rhoda W. Y. Law, Andrew J. Elia, Ben X. Wang, Ian King, Tong Zhang, Trevor J. Pugh, Zaid Saeed Kamil, Marcus Butler, Frances A. Shepherd, Natasha B. Leighl, Albiruni Abdul Razak, Aaron Hansen, Samuel D. Saibil, Philippe L. Bedard, Peter M. Siegel, Lillian L. Siu, David W. Cescon, Anna Spreafico
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2026-01-01
Serie:	Nature Communications
Accesso online:	https://doi.org/10.1038/s41467-025-68076-7
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!